\-\ Texto\\:\\ \ \(0\)\
\-\ during\\ his\\ evaluation\\,\\ radiologic\\ studies\\ had\\ disclosed\\ a\\ contrast\\ enhancing\\ lesion\\ in\\ the\\ fourth\\ ventricle\\.\\ he\\ had\\ no\\ symptoms\\ directly\\ referable\\ to\\ the\\ fourth\\ ventricular\\ lesion\\.\\ craniotomy\\ and\\ removal\\ of\\ the\\ fourth\\ ventricular\\ tumor\\ was\\ eventually\\ performed\\.\ \(0\)\
\-\ contrast\\ enhancing\\ mass\\ in\\ the\\ inferior\\ portion\\ of\\ the\\ fourth\\ ventricle\ \(0\)\
\-\ subependymoma\\ of\\ the\\ fourth\\ ventricle\ \(0\)\
\-\ choroid\\ plexus\\ papilloma\ \(11\)\
\-\ choroid\\ plexus\\ metastasis\ \(0\)\
\-\ subependymoma\ \(6\)\
\-\ this\\ 66\\ year\\-old\\ man\\ developed\\ optic\\ neuritis\\ and\\ visual\\ loss\\ in\\ his\\ right\\ eye\\ that\\ resolved\\ with\\ steroid\\ treatment\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ fourth\\:\\ 0\\.24603495219299276\ \(0\)\
\-\ subependymoma\\:\\ 0\\.14387927861254088\ \(0\)\
\-\ ventricle\\:\\ 0\\.11437108277065813\ \(0\)\
\-\ choroid\\:\\ 0\\.10383740780269024\ \(0\)\
\-\ plexus\\:\\ 0\\.09885903166320074\ \(0\)\
\-\ ventricular\\:\\ 0\\.09091205119529483\ \(0\)\
\-\ referable\\:\\ 0\\.08178105089179981\ \(0\)\
\-\ disclosed\\:\\ 0\\.0801913914557936\ \(0\)\
\-\ neuritis\\:\\ 0\\.0644562028845755\ \(0\)\
\-\ enhancing\\:\\ 0\\.06380841744963713\ \(0\)\
\-\ craniotomy\\:\\ 0\\.061031416307768586\ \(0\)\
\-\ his\\:\\ 0\\.05864021494397457\ \(0\)\
\-\ eventually\\:\\ 0\\.05600767333087127\ \(0\)\
\-\ directly\\:\\ 0\\.05581409570144531\ \(0\)\
\-\ 66\\:\\ 0\\.05471441331893323\ \(0\)\
\-\ steroid\\:\\ 0\\.05370777774717057\ \(0\)\
\-\ radiologic\\:\\ 0\\.05292941156546996\ \(0\)\
\-\ papilloma\\:\\ 0\\.05111583151092212\ \(0\)\
\-\ resolved\\:\\ 0\\.04931773320838799\ \(0\)\
\-\ optic\\:\\ 0\\.047091738328628875\ \(0\)\
\-\ visual\\:\\ 0\\.0461175714447285\ \(0\)\
\-\ contrast\\:\\ 0\\.04554227825733108\ \(0\)\
\-\ had\\:\\ 0\\.04390118617239781\ \(0\)\
\-\ eye\\:\\ 0\\.04267154532276085\ \(0\)\
\-\ lesion\\:\\ 0\\.04144179109524892\ \(0\)\
\-\ removal\\:\\ 0\\.040104536336907\ \(0\)\
\-\ developed\\:\\ 0\\.03916744624803231\ \(0\)\
\-\ metastasis\\:\\ 0\\.03808032531309436\ \(0\)\
\-\ studies\\:\\ 0\\.037994058544989995\ \(0\)\
\-\ year\\-old\\:\\ 0\\.03736624549640734\ \(0\)\
\-\ portion\\:\\ 0\\.036847698182846264\ \(0\)\
\-\ inferior\\:\\ 0\\.03451567096856027\ \(0\)\
\-\ during\\:\\ 0\\.031131062499092952\ \(0\)\
\-\ evaluation\\:\\ 0\\.029550461855081044\ \(0\)\
\-\ loss\\:\\ 0\\.02952933538652904\ \(0\)\
\-\ he\\:\\ 0\\.02838318264325023\ \(0\)\
\-\ performed\\:\\ 0\\.028364027752706175\ \(0\)\
\-\ symptoms\\:\\ 0\\.025353065201168323\ \(0\)\
\-\ man\\:\\ 0\\.024058712417738083\ \(0\)\
\-\ tumor\\:\\ 0\\.023717051209652514\ \(0\)\
\-\ treatment\\:\\ 0\\.020590678090486748\ \(0\)\
\-\ that\\:\\ 0\\.0175711991495098\ \(0\)\
\-\ in\\:\\ 0\\.015049901076437675\ \(0\)\
\-\ mass\\:\\ 0\\.01414834532080434\ \(0\)\
\-\ was\\:\\ 0\\.011765208597781985\ \(0\)\
\-\ this\\:\\ 0\\.011442109682311108\ \(0\)\
\-\ right\\:\\ 0\\.010733710822743055\ \(0\)\
\-\ no\\:\\ 0\\.010243382746473833\ \(0\)\
\-\ the\\:\\ 0\\.009874948907401843\ \(0\)\
\-\ to\\:\\ 0\\.0050841441481307885\ \(0\)\
\-\ a\\:\\ 0\\.004721426212126205\ \(0\)\
\-\ and\\:\\ 0\\.004285928707909963\ \(0\)\
\-\ of\\:\\ 0\\.004160850028499586\ \(0\)\
\-\ \\,\\:\\ 0\\.003222738875205802\ \(0\)\
\-\ \\.\\:\\ 0\\.001690454099873632\ \(0\)\
\-\ with\\:\\ 0\\.0013929068582129729\ \(0\)\
